Latest news with #IFHAS
Al Etihad
15-05-2025
- Health
- Al Etihad
ADPHC signs strategic partnership agreement with Institute for Healthier Living Abu Dhabi to enhance community health and wellbeing
15 May 2025 23:40 ABU DHABI (ALETIHAD)The Abu Dhabi Public Health Centre (ADPHC) has signed a strategic partnership agreement with the Institute for Healthier Living Abu Dhabi (IHLAD) to further enhance the community's health and well-being through innovation, personalised care, and targeted lifestyle early interventions. The agreement was signed on the sidelines of the 25th IUHPE World Conference on Health Promotion, a global event hosted in Abu Dhabi for the first time in the Middle East, under the theme Settings for Planetary Health and and IHLAD are collaborating to improve the lives of Abu Dhabi's residents through preventing and managing lifestyle-related diseases, including diabetes, heart disease, obesity, hypertension, and other cardiometabolic to the agreement, IHLAD will utilise the health data extracted from the comprehensive health screening programme (IFHAS). The institute will enrol participants through voluntary consent. Individuals will be classified according to age, gender and clinical risk factors. Participants will receive specialised care, following an exceptional proactive therapeutic approach, through the integration of advanced diagnostic technologies and evidence-based preventive strategies to more effectively treat lifestyle-related diseases. Dr. Rashed Obaid Alsuwaidi, Director General of the Abu Dhabi Public Health Centre (ADPHC), said: 'Abu Dhabi Public Health Centre's strategic partnership with the Institute for Healthier Living Abu Dhabi (IHLAD) serves as a testament to our commitment to enhance the health and well-being of all community members. Through this collaboration, we remain dedicated to empowering our community to lead longer, healthier lives by prioritising proactive preventative approaches, early detection and integration of cutting-edge innovations in data analytics, life science and artificial intelligence (AI) across the healthcare ecosystem.'In Abu Dhabi, we leverage the Malaffi platform and the comprehensive health screening programme (IFHAS) to gather valuable insights on the population's health needs. These initiatives enable us to support community members in adopting healthy lifestyles that enhance their current and future well-being.'Dr. Nicole Sirotin, CEO of the Institute for Healthier Living Abu Dhabi, said: 'The Institute for Healthier Living Abu Dhabi is collaborating closely with Abu Dhabi Public Health Centre (ADPHC) and other UAE government entities to develop a comprehensive, forward-thinking approach to enhancing the health and longevity of the UAE's population. By harnessing advanced technology, artificial intelligence, and precision lifestyle medicine, we are transforming the healthcare system into one that proactively identifies individuals at high risk for disease and implements personalised, preventive strategies to mitigate complications before they arise.'Innovative diagnostics, such as biomarkers, AI-based retinal scans and multi-omics testing, will be introduced to advance early detection and diagnosis. Personalised nutrition and fitness plans, designed with evidence from the American College of Lifestyle Medicine and other prestigious global entities, will empower individuals to make informed health Department of Health – Abu Dhabi has recently announced the introduction of a groundbreaking licensing framework to establish Healthy Longevity Medicine Centres (HLMCs). This initiative, the first of its kind globally, enables the centres to provide a wide range of services to promote wellness, longevity, and disease prevention for the residents of Abu Dhabi. The department has also announced the licensing of IHLAD as the first specialised Healthy Longevity Medicine Centre in the world. Organised by the Abu Dhabi Public Health Centre (ADPHC) in collaboration with the International Union for Health Promotion and Education (IUHPE), the 25th IUHPE World Conference on Health Promotion brings together more than 2,000 global experts, policymakers, and practitioners to explore practical solutions to today's most pressing public health challenges. With a focus on prevention, innovation, and cross-sector collaboration, the event reflects Abu Dhabi's growing role as a hub for sustainable, inclusive, and forward-looking public health systems. Source: Aletihad - Abu Dhabi
Associated Press
30-01-2025
- Health
- Associated Press
Guardant Health's Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an agreement with the Abu Dhabi Public Health Center (ADPHC) to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant's Shield™ test. The agreement was set up through Hikma Pharmaceuticals PLC, a multinational pharmaceutical group and regional partner for Guardant in the Middle East and North Africa, and will be administered by the M42 healthcare system. 1 Colorectal cancer is the third most common type of cancer in Abu Dhabi, with 63% of cases diagnosed at a late stage, which adversely affects health outcomes and lowers survival rates. 2 The introduction of the Shield blood test is intended to be a significant step forward in improving screening participation, early detection and outcomes for the community. The Shield test will be provided as part of the ADPHC's IFHAS comprehensive health screening program and will be available at major healthcare facilities operated by Ambulatory Healthcare Services and M42 sites across Abu Dhabi, Al Ain, and the Al Dhafra region. This broad accessibility and the more pleasant screening experience are expected to address low adherence rates, a key challenge in the early detection of colorectal cancer. 'Early detection of colorectal cancer can dramatically improve survival rates,' said AmirAli Talasaz, Guardant Health co-CEO. 'This new population screening program by the Department of Health in Abu Dhabi prioritizes community health by providing a more pleasant screening option that can help increase early detection and improve outcomes for the people of the UAE.' The blood-based colorectal cancer screening program is expected to screen approximately 10,000 people across Abu Dhabi and surrounding regions in its first year. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. Zarak Khurshid [email protected] Contact: Michael Weist [email protected] +1 317-371-0035 SOURCE: Guardant Health, Inc. Copyright Business Wire 2025. PUB: 01/30/2025 08:05 AM/DISC: 01/30/2025 08:05 AM
